Atlanta Consulting Group Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Atlanta Consulting Group Advisors's VRTX Position: Q2 2026 in Review
Atlanta Consulting Group Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 405 shares worth $201K. The stake represents 0.03% of the portfolio and ranks #182 among its holdings. This is a return to the name: Atlanta Consulting Group Advisors previously reported a position in VRTX as recently as Q1 2025.
Atlanta Consulting Group Advisors first reported a position in VRTX in Q2 2024 and has held it in 4 quarters since. The position peaked at $823K in Q3 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Atlanta Consulting Group Advisors held 405 shares of Vertex Pharmaceuticals worth $201K as of Q2 2026.
- Vertex Pharmaceuticals was a new Atlanta Consulting Group Advisors position in Q2 2026.
- Vertex Pharmaceuticals made up 0.03% of Atlanta Consulting Group Advisors's portfolio in Q2 2026, its #182 holding.
- Atlanta Consulting Group Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
- Atlanta Consulting Group Advisors's Vertex Pharmaceuticals position peaked at $823K in Q3 2024.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Atlanta Consulting Group Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.